植入式闭环神经刺激器系统用于治疗难治性癫痫的有效性和安全性的前瞻性、多中心、单盲、随机对照临床试验

注册号:

Registration number:

ChiCTR2200059615 

最近更新日期:

Date of Last Refreshed on:

2026-02-04 17:12:01 

注册时间:

Date of Registration:

2022-05-04 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

植入式闭环神经刺激器系统用于治疗难治性癫痫的有效性和安全性的前瞻性、多中心、单盲、随机对照临床试验

Public title:

A Prospective, Multicenter, Single-Blind, Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of an Implantable Closed-Loop Neurostimulator System for the Treatment of Refractory Epilepsy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

植入式闭环神经刺激器系统用于治疗难治性癫痫的有效性和安全性的前瞻性、多中心、单盲、随机对照临床试验

Scientific title:

A Prospective, Multicenter, Single-Blind, Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of an Implantable Closed-Loop Neurostimulator System for the Treatment of Refractory Epilepsy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

葛钰 

研究负责人:

周健 

Applicant:

Ge Yu 

Study leader:

Zhou Jian 

申请注册联系人电话:

Applicant telephone:

+86 182 0611 2617

研究负责人电话:

Study leader's
telephone:

+86 139 1109 8389

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

gey@rishena.com

研究负责人电子邮件:

Study leader's E-mail:

zhoujian5151@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省常州市新北区华山中路 26 号

研究负责人通讯地址:

北京市海淀区香山一棵松50号

Applicant address:

No.26, Huashan Middle Road, Xinbei District, Changzhou, Jiangsu

Study leader's address:

No.50, Yisong, Xiangshan District, Haidian District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

常州瑞神安医疗器械有限公司

Applicant's institution:

Changzhou Ruishen'an Medical Instrument Co., Ltd.

研究负责人所在单位:

首都医科大学三博脑科医院

Affiliation of the Leader:

Sanbo Brain Hospital, Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SBNK-QX-2022-002-01; SBNK-QX-2022-002-02; SBNK-QX-2022-002-03; SBNK-QX-2022-002-04; SBNK-QX-2022-002-05; SBNK-QX-2022-002-06; 临械审[2022]014号; 临械审[2022]014号-008-修正1; 临械审[2022]014号-008-修正2; 临械审 [2022]014号-010-年审2; 临械审 [2022]014号-011-年审3

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学三博脑科医院伦理委员会;首都医科大学宣武医院伦理委员会

Name of the ethic committee:

Ethics Committee of Sanbo Brain Hospital, Capital Medical University; Ethics Committee of Xuanwu Hospital ,Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2022-04-13 00:00:00

伦理委员会联系人:

王彦

Contact Name of the ethic committee:

Wang Yan

伦理委员会联系地址:

北京市海淀区香山路一棵松50号1号楼3层301室

Contact Address of the ethic committee:

50, Yisong, Xiangshan Road, Haidian District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 6285 6766

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

首都医科大学三博脑科医院;首都医科大学宣武医院

Primary sponsor:

Sanbo Brain Hospital, Capital Medical University; Xuanwu Hospital, Capital Medical University

研究实施负责(组长)单位地址:

北京市海淀区香山一棵松50号; 北京市西城区长椿街45号

Primary sponsor's address:

50 Yisong, Xiangshan District, Haidian District, Beijing; 45 Changchun Street, Xicheng District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

常州

Country:

China

Province:

Jiangsu

City:

Changzhou

单位(医院):

常州瑞神安医疗器械有限公司

具体地址:

江苏省常州市新北区华山中路

Institution
hospital:

Changzhou Ruishen'an Medical Instrument Co., Ltd.

Address:

26, Huashan Middle Road, Xinbei District, Changzhou, Jiangsu

经费或物资来源:

常州瑞神安医疗器械有限公司

Source(s) of funding:

Changzhou Ruishen'an Medical Instrument Co., Ltd.

研究疾病:

药物难治性癫痫  

Target disease:

Medically intractable epilepsy

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

验证植入式闭环神经刺激器系统(Implantable Closed-loop Neurostimulator System,CNS)用于治疗药物难治性癫痫的有效性和安全性。  

Objectives of Study:

To verify the efficacy and safety of Implantable Closed-loop Neurostimulator System (CNS) in the treatment of medically intractable epilepsy.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.曾经接受过DBS植入;
2.体内有主动性植入物如心脏起搏器、除颤器、人工耳蜗、药物输注泵、其他神经刺激器等,或有影响刺激器系统的被动性植入物;如患者体内已有植入式迷走神经刺激器(VNS),关闭VNS后可参加本试验;
3.存在神经外科手术禁忌证,以及严重的心脑血管病者;
4.有临床意义或不稳定的身体状况(包括酒精和/或药物滥用)或进行性中枢神经系统疾病;
5.合并肝、肾功能严重异常等严重影响健康的系统性疾病;
6.妊娠或近一年有妊娠意向的女性、哺乳期女性;
7.研究者判断受试者依从性差,或不适宜参加临床试验的受试者。

Exclusion criteria:

1. Have received DBS implantation;
2. Active implants such as cardiac pacemakers, defibrillators, cochlear implants, drug infusion pumps, other nerve stimulators, or passive implants that affect the stimulator system; If the patient has an implanted vagus nerve stimulator (VNS) in his body, he can participate in this test after turning off VNS;
3. Patients with neurosurgical contraindications and serious cardio-cerebrovascular diseases;
4. Clinically significant or unstable physical condition (including alcohol and/or drug abuse) or progressive central nervous system disease;
5. Systemic diseases that seriously affect health, such as severe abnormal liver and kidney functions;
6. Women who are pregnant or have intention of pregnancy in the past year, and women in lactation;
7. Subjects judged by the researcher as having poor compliance or not suitable for clinical trials.

研究实施时间:

Study execute time:

From 2022-08-03 00:00:00 To 2026-06-08 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-08-03 00:00:00 To 2025-05-08 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

33

Group:

treatment group

Sample size:

干预措施:

植入式闭环神经刺激器系统,术后14天开机

干预措施代码:

Intervention:

Implantable Closed-Loop Neurostimulator System, active stimulation after 14 days of surgery.

Intervention code:

组别:

对照组

样本量:

33

Group:

control group

Sample size:

干预措施:

植入式闭环神经刺激器系统,术后14天假开机,90天真开机

干预措施代码:

Intervention:

Implantable Closed-Loop Neurostimulator System, shame stimulation after 14 days of surgery, and active stimulation after 90 days of surgery.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

CHina

Province:

Beijing

City:

单位(医院):

首都医科大学三博脑科医院 

单位级别:

三级 

Institution
hospital:

Sanbo Brain Hospital, Capital Medical University

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学宣武医院 

单位级别:

三甲 

Institution
hospital:

Xuanwu Hospital Capital Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

中国人民解放军总医院 

单位级别:

三甲 

Institution
hospital:

Chinese PLA General Hospital

Level of the institution:

Grade 3 Grade A

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海交通大学医学院附属瑞金医院卢湾分院 

单位级别:

二甲 

Institution
hospital:

Ruijin Hospital Luwan Branch, Shanghai Jiao Tong University School of Medicine

Level of the institution:

Secondary A

国家:

中国

省(直辖市):

江苏 

市(区县):

南京 

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

南京大学医学院附属鼓楼医院 

单位级别:

三甲 

Institution
hospital:

Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

江苏 

市(区县):

南京 

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

南京脑科医院 

单位级别:

三甲 

Institution
hospital:

Nanjing Brain Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

江西 

市(区县):

南昌 

Country:

China

Province:

Jiangxi

City:

Nanchang

单位(医院):

南昌大学第二附属医院 

单位级别:

三甲 

Institution
hospital:

The Second Affiliated Hospital of Nanchang University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

辽宁 

市(区县):

沈阳 

Country:

China

Province:

Liaoning

City:

Shenyang

单位(医院):

中国医科大学附属盛京医院 

单位级别:

三甲 

Institution
hospital:

Shengjing Hospital of China Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

福建 

市(区县):

 

Country:

China

Province:

Fujian

City:

单位(医院):

福建医科大学附属第一医院 

单位级别:

三甲 

Institution
hospital:

The Frist Affiliated Hospital Of Fujian Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河北 

市(区县):

 

Country:

China

Province:

Hebei

City:

单位(医院):

河北医科大学第二医院 

单位级别:

三甲 

Institution
hospital:

The Second Hospital Of Hebei Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

徐州医科大学附属医院 

单位级别:

三甲 

Institution
hospital:

The Affiliated Hospital of Xuzhou Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海市 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属华山医院 

单位级别:

三甲 

Institution
hospital:

Fudan University HuaShan Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

盲视评估期(术后90天)时,验证试验组治疗癫痫有效率优于对照组

指标类型:

主要指标

Outcome:

During the blind vision evaluation period (90 days after surgery), verify that the effective rate of the test group in the treatment of epilepsy is better than that of the control group

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

开放标签评估期(术后180天)两组合并,验证治疗癫痫的有效率满足预设目标值的要求。

指标类型:

主要指标

Outcome:

The two groups were combined during the open-label evaluation period (180 days after surgery) to verify that the effective rate for the treatment of epilepsy met the requirements of the preset target value.

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

对照组在盲视评估期内与在开放标签评估期内治疗癫痫有效率的差异。

指标类型:

次要指标

Outcome:

Difference in response rate between the control group during the blind assessment period and the open-label assessment period for the treatment of epilepsy.

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

在开放标签评估期内,对照组和试验组治疗癫痫有效率的差异。

指标类型:

次要指标

Outcome:

Difference in the rate of response to treatment of epilepsy between the control and experimental groups during the open-label evaluation period.

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脑电变化评价(刺激开启前后对比)

指标类型:

次要指标

Outcome:

Evaluation of EEG changes (before and after stimulation)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

研究者对器械使用性能的评价

指标类型:

次要指标

Outcome:

investigator's evaluation of device performance

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

受试者对器械使用性能的评价

指标类型:

次要指标

Outcome:

Subject evaluation of device performance

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

癫痫患者生活质量评分(QOLIE-31)相对基线变化的情况

指标类型:

次要指标

Outcome:

Changes in quality of life score (QolIE-31) relative to baseline in patients with epilepsy

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 10 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由第三方统计公司使用随机化系统产生随机序列。

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number sequence is generated by a third-party statistical company using a randomization system.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

单盲:手术医生和程控医生知晓分组,受试者不知晓。

Blinding:

Single Blind: The surgeons and programmed doctors are unblind, yet the subjects are blind.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例报告表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2022-05-04 23:35:41